There is a major race between three drug companies to release their new weight loss drug to the market. All three new potential diet drugs are showing good results in tests. It is being reported now that these diet drugs are also showing promise to help with other health issues such as high blood pressure, cholesterol, triglycerides and blood-sugar control.

A research team led by Dr. Tony Lam at the Toronto General Research Institute and the University of Toronto discovered a novel function of a hormone found in the gut that might potentially lower glucose levels in diabetes.

Scientists in Sydney and Boston believe they may have identified a gene that controls abnormal production of sugar in the liver, a very troublesome problem for people with diabetes.

In a six-month comparison of low-carb diets, one that encourages eating carbohydrates with the lowest-possible rating on the glycemic index leads to greater improvement in blood sugar control, according to Duke University Medical Center researchers.

Maintaining blood sugar levels, even in the absence of disease, may be an important strategy for preserving cognitive health, suggests a study published by researchers at Columbia University Medical Center (CUMC). The study appeared in the December issue of Annals of Neurology.

When mice that lack steroid receptor-2 (SRC-2) – a master regulator gene called a coactivator – fast for a day, their blood sugar levels plummet. If they go another day without food, they will die.

Herbs and spices are rich in antioxidants, and a new University of Georgia study suggests they are also potent inhibitors of tissue damage and inflammation caused by high levels of blood sugar.

A study reveals today that inadequate blood sugar control in patients having heart surgery is associated with a four fold increase in post-surgery death and major complications - and that the blood sugar disturbances occur in patients with and without diabetes.

Using the Electronic Health Record to actively engage diabetes patients in their own care results in improved blood sugar and cholesterol levels, better vaccination compliance and increased tobacco cessation rates, according to a new Geisinger study.

The results of a major government study on diabetes and heart disease shocked American medical researches, who were going to show that a long-trusted form of treatment for lowering blood sugar would yield even greater results. But the study has raised more questions.

The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped one treatment within a large, ongoing North American clinical trial of diabetes and cardiovascular disease 18 months early due to safety concerns after review of available data, although the study will continue.

The National Institutes of Health announced that they has stopped aggressive diabetes treatment in a major trial after a safety review showed that pushing blood sugar to record low levels sharply increased patients' risk of death.